HLUN-A 📈 H Lundbeck - Overview

H. Lundbeck A/S operates as a biopharmaceutical company, focusing on the research, development, and commercialization of pharmaceutical products aimed at treating psychiatric and neurological disorders. The company's product portfolio includes a range of medications, such as Abilify Maintena, which is used to treat schizophrenia and bipolar I disorder in adults, and Brintellix, also known as Trintellix, for the treatment of depressive disorders. Additionally, Lundbeck offers Northera for symptomatic neurogenic orthostatic hypotension, Vyepti for migraine prevention, and Rexulti, also known as Rxulti, for the treatment of major depressive disorder and schizophrenia.

Lundbeck's product line also encompasses medications for various other conditions, including Azilect for Parkinson's disease, Cipralex, also known as Lexapro, for depression, and Ebixa for the treatment of dementia. The company's portfolio further includes Onfi for epilepsy, Sabril for refractory complex partial seizures and infantile spasms, Xenazine for chorea, Deanxit for depression, Cipramil for depression and anxiety, and Cisordinol for the treatment of psychosis. These products are primarily sold to distributors of pharmaceuticals, pharmacies, and hospitals, facilitating access to these medications for patients across Europe, the United States, and internationally.

In terms of strategic collaborations, Lundbeck has partnered with Otsuka Pharmaceuticals Co., Ltd., a move that underscores the company's commitment to advancing its research and development capabilities. Furthermore, Lundbeck has a collaboration with Alloy Therapeutics, Inc., aimed at the discovery of novel biologics therapies, which could potentially lead to innovative treatments for psychiatric and neurological disorders. Founded in 1915, H. Lundbeck A/S is headquartered in Valby, Denmark, and its common stock is listed under the ISIN DK0061804697, classified under the GICS Sub Industry: Pharmaceuticals.